The role of Levomilnacipran in the management of major depressive disorder: A comprehensive review

Current Neuropharmacology

Volumn 14, Issue 2, 2016, Pages 191-199

  Bruno, Antonio ^a   Morabito, Paolo ^b   Spina, Edoardo ^b   Muscatello, Maria Rosaria ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

Antidepressants; Efficacy; Levomilnacipran extended release; Major depressive disorder; Safety; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CLARITHROMYCIN; DESVENLAFAXINE; DULOXETINE; GAMMA GLUTAMYLTRANSFERASE; KETOCONAZOLE; MILNACIPRAN; NORADRENALIN; PLACEBO; RIFAMPICIN; SEROTONIN; VENLAFAXINE; ANTIDEPRESSANT AGENT; CYCLOPROPANE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ANGINA PECTORIS; ARTICLE; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CONSTIPATION; CONVULSION; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEADACHE; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERHIDROSIS; HYPERTENSION; MAJOR DEPRESSION; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PATIENT SATISFACTION; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY DYSFUNCTION; VOMITING; XEROSTOMIA; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE;

ANTIDEPRESSIVE AGENTS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84960107475     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X14666151117122458     Document Type: Article

References (46)

1. Ferrari, A.J.; Charlson, F.J.; Norman, R.E.; Flaxman, A.D., Patten, S.B., Vos, T., Whiteford, H.A. The epidemiological modelling of major depressive disorder: application for the Global Burden of Disease Study 2010. PLoS One, 2013, 8(7), e69637. http://dx.doi.org/10.1371/journal.pone.0069637
2. Geddes, J.R.; Carney, S.M.; Davies, C.; Furukawa, T.A., Kupfer, D.J., Frank, E., Goodwin, G.M. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet, 2003, 361, 653-661. http://dx.doi.org/10.1016/S0140-6736(03)12599-8
3. Fava, M. Diagnosis and definition of treatment-resistant depression. Biol. Psychiat., 2003, 53, 649-659. http://dx.doi.org/10.1016/S0006-3223(03)00231-2
4. Rozensweig-Lipson, S.; Beyer, C.E.; Hughes, Z.A.; Khawaja, X., Rajarao, S.J., Malberg, J.E., Rahman, Z., Ring, R.H., Schechter, L.E. Differentiating antidepressants of the future: efficacy and safety. Pharmacol. Ther., 2007, 113, 134-143. http://dx.doi.org/10.1016/j.pharmthera.2006.07.002
5. Demyttenaere, K.; Enzlin, P.; Dewe, W.; Boulanger, B., De Bie, J., De Troyer, W., Mesters, P. Compliance with antidepressants in a primary care setting, 1: beyond lack of efficacy and adverse events. J. Clin. Psychiatry, 2001, 62(Suppl 22), 30-33.
6. Papakostas, G.I. Limitations of contemporary antidepressants: tolerability. J. Clin. Psychiatry, 2007, 68 Suppl 10, 11-17.
7. Stahl, S.M.; Grady, M.M.; Moret, C.; Briley, M. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr., 2005, 10, 732-747.
8. Papakostas, G.I.; Thase, M.E.; Fava, M.; Nelson, J.C.; Shelton, R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol. Psychiatry, 2007, 62, 1217-1227. http://dx.doi.org/10.1016/j.biopsych.2007.03.027
9. Forest Pharmaceuticals, Inc. FETZIMA (levomilnacipran extendedrelease capsules). United States Prescribing information. Revised July 2013.
10. Auclair, A.L.; Martel, J.C.; Assie, M.B Bardin, L., Heusler, P., Cussac, D., Marien, M., Newman-Tancredi, A., O'Connor, J.A., Depoortère, R. Levomilnacipran (F2695), a norepinephrinepreferring SNRI: profile in vitro and in models of depression and anxiety. Neuropharmacology, 2013, 70, 338-347. http://dx.doi.org/10.1016/j.neuropharm.2013.02.024
11. Citrome, L. Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int. J. Clin. Pract., 2013, 67, 1089-1104. http://dx.doi.org/10.1111/ijcp.12298
12. Hair, P.; Cameron, F.; Garnock-Jones, K.P. Levomilnacipran Extended Release: First Global Approval. Drugs, 2013, 73, 1639-1645. http://dx.doi.org/10.1177/0897190013516504
13. Saraceni, M.M.; Venci, J.V.; Gandhi, M.A. Levomilnacipran (Fetzima): a new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. J. Pharm. Pract., 2013, 27, 389-395.
14. Mago, R.; Mahajan, R.; Thase, M.E. Levomilnacipran: a newly approved drug for treatment of major depressive disorder. Expert Rev. Clin. Pharmacol., 2014, 7, 137-145. http://dx.doi.org/10.1586/17512433.2014.889563
15. Palmer, E.C.; Binns, L.N.; Carey, H. Levomilnacipran: a new serotonin-norepinephrine reuptake Inhibitor for the treatment of major depressive disorder. Ann. Pharmacother., 2014, 48, 1030-1039. http://dx.doi.org/10.1177/1060028014535074
16. Sansone, R.A.; Sansone, L.A. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov. Clin. Neurosci., 2014, 11, 37-42.
17. Scott, L.J. Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder. CNS Drugs, 2014, 28, 1071-1082. http://dx.doi.org/10.1007/s40263-014-0203-1
18. Deardorff, W.J.; Grossberg, G.T. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine. Expert Opin. Pharmacother., 2014, 15, 2525-2542. http://dx.doi.org/10.1517/14656566.2014.960842
19. Asnis, G.M.; Henderson, M.A. Levomilnacipran for the treatment of major depressive disorder: a review. Neuropsychiatr. Dis. Treat., 2015, 11, 125-135. http://dx.doi.org/10.2147/NDT.S54710
20. Stahl, S.M. Antidepressants. In: Stahl’s Essential Psychopharmacology. 4th ed.; Stahl SM, Ed.; Cambridge University Press: New York, 2013, pp. 284-369.
21. Bymaster, F.P.; Dreshfield-Ahmad, L.J.; Threlkeld, P.G.; Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology, 2001, 25, 871-880. http://dx.doi.org/10.1016/S0893-133X0100298-6
22. Vaishnavi, S.N.; Nemeroff, C.B.; Plott, S.J.; Rao, S.G.; Kranzler, J.; Owens, M.J. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity. Biol. Psychiatry, 2004, 55, 320-322. http://dx.doi.org/10.1016/j.biopsych.2003.07.006
23. Deecher, D.C.; Beyer, C.E.; Johnston, G.; Bray, J., Shah, S., Abou- Gharbia, M., Andree, T.H. Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther., 2006, 318, 657-665. http://dx.doi.org/10.1124/jpet.106.103382
24. Chen, L.; Periclou, A.; Ghahramani, P.; Greenberg, W.M.; Brand-Schieber, E. Pharmacokinetic characteristics of levomilnacipran sustained release capsule following single- and multiple-dose administration. New Research Poster NR9-17, American Psychiatric Association 166th Annual Meeting, San Francisco, CA, 18-22 May 2013.
25. Forest Pharmaceuticals, Inc. Savella (milnacipran HCl) tablets. Prescribing information. Revised December 2012.
26. Chen, L.; Boipally, R.; Greenberg, W.M.; Wangsa, J.; Periclou, A.; Ghahramani, P. Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants. Clin. Drug Investig., 2014, 34, 351-359. http://dx.doi.org/10.1007/s40261-014-0182-5
27. Spina, E.; Trifirò, G.; Caraci, F. Clinically significant drug interactions with newer antidepressants. CNS Drugs, 2012, 26, 39-67. http://dx.doi.org/10.2165/11594710-000000000-00000
28. Montgomery, S.A.; Mansuy, L.; Ruth, A., et al. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. J. Clin. Psychiatry, 2013, 74(4), 363-369. http://dx.doi.org/10.4088/JCP.12m08141
29. Asnis, G.M.; Bose, A.; Gommoll, C.P., Chen, C., Greenberg, W. M. Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry, 2013, 74(3), 242-248. http://dx.doi.org/10.4088/JCP.12m08197
30. Bakish, D.; Bose, A.; Gommoll, C.; Chen, C., Nunez, R., Greenberg, W.M., Liebowitz, M., Khan, A. Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. J. Psychiatry Neurosci., 2014, 39(1), 40-49. http://dx.doi.org/10.1503/jpn.130040
31. Sambunaris, A.; Bose, A.; Gommoll, C.P.; Chen, C., Greenberg, W.M., Sheehan, D.V. A Phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. J. Clin. Psychopharmacol., 2014, 34(1), 1-10. http://dx.doi.org/10.1097/JCP.0000000000000060
32. Gommoll, C.P.; Greenberg, W.M.; Chen, C. A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. J. Drug Assess., 2014, 3, 10-19.
33. Mago, R.; Forero, G.; Greenberg, W.M.; Greenberg, W.M., Gommoll, C., Chen, C. Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48- Week Extension Study. Clin. Drug Investig., 2013, 33(10), 761-771. http://dx.doi.org/10.1007/s40261-013-0126-5
34. Shiovitz, T.; Greenberg, W.M.; Chen, C.; Forero, G.; Gommoll, C.P. A randomized, double-blind, placebo-controlled trial of the efficacy and safety of levomilnacipran ER 40-120 mg/day for prevention of relapse in patients with major depressive disorder. Innov. Clin. Neurosci., 2014, 11(1-2), 10-22.
35. Montgomery, S.A.; Mansuy, L.; Ruth, A.C.; Li, D.; Gommoll, C. The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study. Int. Clin. Psychopharmacol., 2014, 29, 26-35. http://dx.doi.org/10.1097/YIC.0000000000000009
36. Montgomery, S.A.; Gommoll, C.P.; Chen, C.; Greenberg, W.M. Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials. CNS Spectr., 2014, 5, 1-9.
37. Sambunaris, A.; Gommoll, C.; Chen, C.; Greenberg, W.M. Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials. Int. Clin. Psychopharmacol., 2014, 29, 197-205. http://dx.doi.org/10.1097/YIC.0000000000000033
38. Blum, S.I.; Tourkodimitris, S.; Ruth, A. Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. J. Affect. Disord., 2015, 170, 230-236. http://dx.doi.org/10.1016/j.jad.2014.09.005
39. Acquadro, C.; Berzon, R.; Dubois, D.; Leidy, N.K.; Marquis, P.; Revicki, D.; Rothman, M. PRO Harmonization Group. Incorporating the patient's perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health, 2003, 6(5), 522-531. http://dx.doi.org/10.1046/j.1524-4733.2003.65309.x
40. Thase, M.E. Update on partial response in depression. J. Clin. Psychiatry, 2009, 70 (Suppl 6), 4-9. http://dx.doi.org/10.4088/JCP.8133su1c.01
41. Bergner, M. Quality of life, health status, and clinical research. Med. Care, 1989, 27, S148-156. http://dx.doi.org/10.1097/00005650-198903001-00012
42. Patrick, D.L.; Erickson, P. Health Status and Health Policy: Allocating Resources to Health Care. New York: Oxford University Press, 1993.
43. Nutt, D. J. Relationship of neurotransmitters to the symptoms of major depressive disorder. J. Clin. Psychiatry, 2008, 69(Suppl E1), 4-7.
44. Bradley, A.J.; Lenox-Smith, A.J. Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. J. Psychopharmacol., 2013, 27, 740-758. http://dx.doi.org/10.1177/0269881113494937
45. Sansone, R.A.; Sansone, L.A. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov. Clin. Neurosci., 2014, 11(3-4), 37-42.
46. Dell’Osso, B.; Palazzo, M.C.; Oldani, L.; Altamura, A.C. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci. Ther., 2011, 17(6), 723-732. http://dx.doi.org/10.1111/j.1755-5949.2010.00217.x